News

Omicron-specific boosters fail to show benefit over original shots, study finds

By Abigail Adcox
Published October 25, 2022 9:12pm ET
Add Washington Examiner on Google
Omicron-specific boosters fail to show benefit over original shots, study finds
The newest omicron COVID-19 booster shots from Moderna and Pfizer-BioNTech do not increase neutralizing antibodies, proteins produced in the body that help prevent infection, against omicron subvariants BA.4 and BA.5 compared to four of the original COVID-19 shots, according to a small-scale independent study. Researchers at Columbia University and the University of Michigan found that […]

The newest omicron COVID-19 booster shots from Moderna and Pfizer-BioNTech do not increase neutralizing antibodies, proteins produced in the body that help prevent infection, against omicron subvariants BA.4 and BA.5 compared to four of the original COVID-19 shots, according to a small-scale independent study.

Already a print subscriber? Click here to login/register your account

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.

Tag:

COVID-19 Pfizer research Vaccines